Recent Updates
Recently added Catalysts
OKYO Positive Sentiment Score: 75/100

OKYO Pharma to Present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference

Tuesday, July 21, 2026 1 min read
Key Takeaway: OKYO Pharma Limited will present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference on July 22, 2026. The presentation will be led by CEO Robert J. Dempsey and CMO Flavio Mantelli. The company is developing therapies for neuropathic corneal pain and plans to initiate a Phase 3 clinical trial for its investigational drug urcosimod.
Price reaction · baseline $1.37 (2026-07-20 close) · hit pre-market · clean, no other OKYO news in the window
day 0 close · peak
+5.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • OKYO Pharma is actively developing innovative therapies for eye diseases.
  • The company is set to present at a significant ophthalmology conference.
  • Plans for a Phase 3 clinical trial indicate progress in their research.

Full Press Release Details

LONDON and NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq:OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced a presentation at the H.C. Wainwright 6thAnnual Ophthalmology Virtual Conference being held on Wednesday, July 22, 2026.

Details of the event are as follows:

Presenter:Robert J. Dempsey, Chief Executive Officer, Flavio Mantelli MD, PhD, Chief Medical OfficerDate/Time:Wednesday, July 22, 12:30 PM ETLocation:VirtualRegister to Attend:H.C. Wainwright Registration
About OKYOPharmaOKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP.
For further information, please visitwww.okyopharma.com.

For further inquiries:

OKYO Pharma LtdPaul SpencerBusiness Development and Investor Relations+44 (0) 207 495 2379Email:info@okyopharma.com

Frequently Asked Questions

When is OKYO Pharma's presentation at the conference?

The presentation is scheduled for July 22, 2026, at 12:30 PM ET.

Who will present for OKYO Pharma?

CEO Robert J. Dempsey and CMO Flavio Mantelli will present.

What is the focus of OKYO Pharma's research?

OKYO Pharma focuses on therapies for neuropathic corneal pain and eye diseases.

What trial is OKYO Pharma planning to initiate?

They plan to start a Phase 3 clinical trial for urcosimod.

Tags: OKYO Viatris Investor Conferences Healthcare OKYO Pharma ophthalmology clinical trial neuropathic corneal pain urcosimod
Last updated: Jul 21, 2026